海關總署召回雅培中國一款特醫產品 提醒消費者暫勿購買有關奶粉
國家海關總署表示,雅培生產的特醫產品Similac HMFortifi喜康寶貝添特殊醫學用途嬰兒營養補充劑有對華出口記錄,雅培中國已啓動自主召回。
據美國食品和藥品監督管理局(FDA)近日正在調查四名嬰兒感染克羅諾桿菌和沙門氏菌事件的投訴,稱該四名嬰兒均食用雅培奶粉,品牌包括Similac、Alimentum和EleCare。
經國家海關總署覈查,相關產品沒有通過一般貿易輸華,但提醒消費者,暫不要通過任何渠道購買該嬰幼兒配方奶粉。如有通過海淘等非一般貿易渠道購買雅培相關批次嬰幼兒配方奶粉的,立即暫停食用。如有購買該特醫產品的,立即暫停食用。(ta/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.